Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MASP2 | O00187 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 4/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311168 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4EGPR3TOP2AHPGD | |
| SCHEMBL311958 | 0.79 | PARP1 (0.51) | ALDH1A1KDM4EGPR3TYMSTOP2A | |
| SCHEMBL5137072 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4EGPR3TOP2AHPGD | |
| SCHEMBL5341134 | 0.78 | LOXL2 (0.42) | KMT2AKDM4EGPR3TOP2API4KB | |
| SCHEMBL10771264 | 0.78 | TNKS (0.58) | ALDH1A1KMT2AMEN1KDM4ETOP2A | |
| SCHEMBL1486423 | 0.77 | KDM4E (0.44) | ALDH1A1KDM4EGPR3TOP2API4KB | |
| SCHEMBL1490778 | 0.76 | NUDT1 (0.42) | QTRT1ALDH1A1KMT2AMASP2MEN1 | |
| SCHEMBL1423662 | 0.76 | TNKS (0.56) | ALDH1A1TOP2AHPGDHSD17B10RAB9A | |
| SCHEMBL9378888 | 0.76 | TOP2A (0.42) | ALDH1A1KDM4EGPR3TOP2AHPGD | |
| SCHEMBL2088588 | 0.75 | ERN1 (0.45) | KMT2AKDM4EGPR3TOP2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699573-A2 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | claimed |
| WO-2012143416-A2 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | claimed |
| US-6610319-B2 | Administering imiquimod | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-26 | — | — | US | claimed |
| EP-2830629-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | Icahn School of Medicine Mount Sinai (US) | 2015-02-04 | — | — | EP | disclosed |
| US-8871782-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8778963-B2 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2699573-A2 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2013148197-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2012143416-A2 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| WO-2006029115-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| US-6780873-B2 | FOR INDUCING CYTOKINE BIOSYNTHESIS IN ANIMALS, AND IN THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-24 | — | — | US | disclosed |
| EP-0912565-B1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | MINNESOTA MINING & MFG (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-0708781-B1 | A 3 ADENOSINE RECEPTOR AGONISTS | USA (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-0802913-B1 | IMIDAZO [4,5-c]QUINOLINE AMINES | MINNESOTA MINING & MFG (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0802913-A1 | IMIDAZO 4,5-c]QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021663-A1 | IMIDAZO[4,5-c]QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-07-18 | — | — | WO | disclosed |
| US-5482936-A | INDUCE INTERFERON BIOSYNTHESIS IN AN ANIMAL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | QTRT1 2548/4885ALDH1A1 918/4885KMT2A 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.